Chris Whitehouse, a political consultant and expert on medical technology policy and regulation at Whitehouse Communications, an advisor to MedTech suppliers, chair of the Urology Trade Association, and governor of the Anscombe Bioethics Centre, highlights the importance of a new EU consultation on procurement and the opportunities it presents for the MedTech sector.
The European Union [EU] has initiated a comprehensive consultation process aimed at reforming procurement regulations across its member states. This move presents a significant opportunity for stakeholders in the procurement sector to advocate for a shift towards value-based procurement, which prioritises quality and long-term benefits over mere cost considerations.
Background and Objectives
Public procurement in the EU is a substantial economic activity, accounting for approximately 14% of the EU's gross domestic product. The current legal framework, established by the Public Procurement Directives of 2014, was designed to enhance flexibility, simplify procedures, and improve access for small and medium-sized enterprises [SMEs]. But, recent evaluations suggest that these objectives have not been fully realised.
The European Commission has launched a call for evidence and a public consultation to gather feedback on the performance of these directives. This consultation aims to assess whether the directives remain fit for purpose, achieve their intended objectives cost-effectively, and address current challenges.
Opportunities for Value-Based Procurement
One of the key areas for the MedTech sector to focus in the consultation, and the subsequent discussions in the EU institutions, is the potential for value-based procurement. This approach emphasises the overall value delivered by procurement contracts, including factors such as quality, sustainability, and social impact, rather than focusing solely on the lowest price.
Advocates for value-based procurement argue that it can lead to better outcomes for public services and infrastructure projects. By considering the long-term benefits and total cost of ownership, value-based procurement can ensure that public funds are used more efficiently and effectively – and most importantly deliver improved experience and outcomes for patients.
Stakeholder Engagement
The consultation process is open until March 7, 2025, and the Commission is encouraging all interested parties to participate. This includes public authorities, businesses, and civil society organisations. Stakeholders are invited to share their experiences, provide data, and suggest improvements to the current procurement framework.
The feedback collected will be crucial in shaping the future of procurement regulations in the EU. It will help identify obstacles to effective procurement and explore ways to simplify and enhance the regulatory environment.
The MedTech sector across the EU and beyond should engage with this process to deliver a paradigm shift in healthcare purchasing regulation, policy and practice.
The Author used AI in preparing this article. Comments upon or questions about this article can be addressed to chris.whitehouse@whitehousecomms.com.
